The FDA Has Approved Niraparib (Zejula) for Platinum-Sensitive Recurrent Ovarian Cancer
source: pixabay.com

The FDA Has Approved Niraparib (Zejula) for Platinum-Sensitive Recurrent Ovarian Cancer

Dr. Oliver Dorigo of the Stanford University Medical Center was the medical source for an article featured in Oncology. Dr. Dorigo explained that if a woman with ovarian cancer has…

Continue Reading The FDA Has Approved Niraparib (Zejula) for Platinum-Sensitive Recurrent Ovarian Cancer

Study of the Week: New Genetic Predisposition Variants in Rhabdomyosarcoma

Welcome to Study of the Week from Patient Worthy. In this segment, we select a study we posted about from the previous week that we think is of particular interest…

Continue Reading Study of the Week: New Genetic Predisposition Variants in Rhabdomyosarcoma
Tel Aviv University Team Uses CRISPR Technique to Destroy Metastatic Cancer Cells in Mice
source: pixabay.com

Tel Aviv University Team Uses CRISPR Technique to Destroy Metastatic Cancer Cells in Mice

     The latest news from Israeli scientists, published in the Times of Israel, is that researchers at Tel Aviv University have accurately targeted cancerous cells in mice using CRISPR.…

Continue Reading Tel Aviv University Team Uses CRISPR Technique to Destroy Metastatic Cancer Cells in Mice
New Combination for HRD-Positive Ovarian Cancer Gets EU Approval
source: pixabay.com

New Combination for HRD-Positive Ovarian Cancer Gets EU Approval

According to a story from Cancer Network, the European Commission has recently approved a two-part combination treatment for advanced, homologous recombination deficiency (HRD)-positive ovarian cancer. This first-line maintenance treatment consists…

Continue Reading New Combination for HRD-Positive Ovarian Cancer Gets EU Approval
A Negative Side Effect of COVID-19: Reduced Cancer Screenings
Photo by National Cancer Institute on Unsplash

A Negative Side Effect of COVID-19: Reduced Cancer Screenings

In her early 20's, Mackenzie Alleman lost her mother to breast cancer. Then, at 28, she herself underwent a preventative double mastectomy after learning that she carried the mutated BRCA1 gene.…

Continue Reading A Negative Side Effect of COVID-19: Reduced Cancer Screenings

The FDA has Extended Approval of Zejula for Ovarian Cancer Patients With and Without BRCA Mutations

GlaxoSmithKline (GSK) has just announced that Zejula, otherwise known as niraparib, has just been approved for cancer patients beyond those who have a BRCA+ mutation. The patients now included in…

Continue Reading The FDA has Extended Approval of Zejula for Ovarian Cancer Patients With and Without BRCA Mutations
Potential Treatment for BRCA Mutated Pancreatic Cancer Performs Well in Trial
mohamed_hassan / Pixabay

Potential Treatment for BRCA Mutated Pancreatic Cancer Performs Well in Trial

According to a story from BioPortfolio, AstraZeneca and Merck have recently announced the results from a phase 3 clinical trial testing olaparib (marketed as LYNPARZA®) as a treatment for BRCA…

Continue Reading Potential Treatment for BRCA Mutated Pancreatic Cancer Performs Well in Trial

CRISPR Uncovers New Gene Fusion as Novel Drug Target for Brain, Ovarian and other Cancers

  CRISPR-Cas9, the genome editing tool, has caused quite a stir in the scientific community. According to a recent article in Science Daily, with results published in Nature Communications, CRISPR has…

Continue Reading CRISPR Uncovers New Gene Fusion as Novel Drug Target for Brain, Ovarian and other Cancers
Trial Data Reveals Improved Quality of Life for Ovarian Cancer Patients Taking Rucaparib
stevepb / Pixabay

Trial Data Reveals Improved Quality of Life for Ovarian Cancer Patients Taking Rucaparib

According to a story from BioPortfolio, the biopharmaceutical company Clovis Oncology, Inc. recently released data from a phase 3 clinical trial of patients with recurrent ovarian cancer taking the company's…

Continue Reading Trial Data Reveals Improved Quality of Life for Ovarian Cancer Patients Taking Rucaparib
Could This Investigational Drug be a New Treatment Option for Acute Myeloid Leukemia?
qimono / Pixabay

Could This Investigational Drug be a New Treatment Option for Acute Myeloid Leukemia?

According to a story from globenewswire.com, the biopharmaceutical company Innovation Pharmaceuticals recently released a report in which recent studies and pre-clinical research has suggested that the company's experimental drug Kevetrin…

Continue Reading Could This Investigational Drug be a New Treatment Option for Acute Myeloid Leukemia?